Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H14N2O2S |
Molecular Weight | 334.392 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1SN(C(=O)N1CC2=CC=CC=C2)C3=CC=CC4=C3C=CC=C4
InChI
InChIKey=PMJIHLSCWIDGMD-UHFFFAOYSA-N
InChI=1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2
Molecular Formula | C19H14N2O2S |
Molecular Weight | 334.392 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Tideglusib (NP031112, NP-12, Nypta, Noscira SA, Madrid, Spain), a drug, which belongs to the thiadiazolidinone family, is a GSK-3β inhibitor. Tideglusib was in phase II clinical trials for the treatment of Alzheimer disease (AD) and progressive supranuclear palsy. Participants showed no benefit on either of the primary outcome measures or exploratory endpoints and further development in the drug was halted for these two disease. However, Tideglusib is on phase II clinical trial to determine whether drug is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P49841 Gene ID: 2932.0 Gene Symbol: GSK3B Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/22102280 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. | 2011 |
|
Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. | 2011 Dec 22 |
|
Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. | 2011 Jun 23 |
|
Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. | 2012 Jan 6 |
|
Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. | 2013 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01350362
1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22102280
Tideglusib is an irreversible inhibitor of GSK-3β. The interaction of tideglusib with GSK-3β, binding studies with radioactive compound were performed. [35S]tideglusib (207 Bq/nmol) at 55 μM was incubated with 5 μM GSK-3β for 1 h at 25 °C in 315 μl of 50 mM Tris-HCl, pH 7.5, containing 150 mM NaCl and 0.1 mM EGTA.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:25:10 GMT 2023
by
admin
on
Fri Dec 15 17:25:10 GMT 2023
|
Record UNII |
Q747Y6TT42
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/15/1452
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
||
|
FDA ORPHAN DRUG |
290109
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
||
|
FDA ORPHAN DRUG |
577417
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
||
|
NCI_THESAURUS |
C471
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11313622
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
PRIMARY | |||
|
DB12129
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
PRIMARY | |||
|
DTXSID90235682
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
PRIMARY | |||
|
100000177254
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
PRIMARY | |||
|
C97364
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545157
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
PRIMARY | |||
|
9223
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
PRIMARY | |||
|
Q747Y6TT42
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
PRIMARY | |||
|
865854-05-3
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
PRIMARY | |||
|
Tideglusib
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
PRIMARY | |||
|
147398
Created by
admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
IRREVERSIBLE INHIBITOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|